PackGene Biotech closes multimillion-yuan Series B led by Cathay Capital

On August 12, Cathay Capital led the Series B financing round in PackGene Biotech, a comprehensive solution provider for viral vector packaging and gene therapy CDMO. The round also saw participation from Oriza Holdings.

On August 12, Cathay Capital led the Series B financing round in PackGene Biotech, a comprehensive solution provider for viral vector packaging and gene therapy CDMO. The round also saw participation from Oriza Holdings.

Proceeds from this round of financing will be mainly used to promote the research and development of biocarrier technology, production platform construction and enterprise management and operation, to further consolidate its leading position in the gene therapy AAV segment.

PackGene Biotech is a company focused on the rapid, large-scale production of recombinant adeno-associated viruses with high purity, high-titer, high-infectivity of gene therapy vectors.

The company is positioned at the core of GMP-grade AAV process and mass production for gene therapy CDMO services, as well as AAV packaging and vector cloning services for researchers, and is committed to providing cost-effective, efficient, scalable and regulatory control of comprehensive AAV vector solutions from basic research, preclinical development and clinical trials.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/14/packgene-biotech-closes-multimillion-yuan-series-b-led-by-cathay-capital/.

Leave a Reply

Your email address will not be published. Required fields are marked *